Background: Administrative claims and medical records are important data sources to examine healthcare utilization and outcomes. Little is known about identifying personalized medicine technologies in these sources.
T he availability of data is critical for research designed to examine health care utilization, clinical practice patterns, and health outcomes. Administrative claims and medical record data are 2 common, important data sources with distinct strengths and limitations. The strengths of administrative claims data are that they are often easy to obtain for covered services with specific codes for billing. Researchers have shown that administrative data can be used to reliably identify incident cancers as well as some aspects of cancer care, such as surgeries and chemotherapy. [1] [2] [3] [4] [5] [6] [7] One downside of administrative data is that the data reflect only the care for which payers were billed. Additionally, even for billed care, billing "bundling" may prevent administrative claims from providing adequate data about specific tests. These data may not contain pathology or radiology reports and often lack detailed clinical information. 8 In contrast, the detailed clinical information from medical records often makes records the preferred data source for research. For example, records offer researchers information on cancer stage and comorbidities. 8 Limitations for using medical record data are that they are costly to obtain, require abstraction, and may be incomplete. 9 There may be additional logistical issues for getting a sample of medical records from a diversity of providers.
Many studies have attempted to assess the agreement between these 2 data sources to understand the utility of using one source versus the other. 8 Studies in cancer and cancer-related care specifically have found agreement between the 2 data sources for use of endoscopy and chemotherapy, but these studies focused on conventional treatments and have analyzed mainly the Medicare population. 1, 10, 11 Relatively little is known about identifying and comparing emerging technologies like personalized medicine technologies in administrative claims and medical records among a commercially insured population.
Two important examples of personalized medicine technologies are the targeted tests and treatments for breast cancer, which are as follows: (1) human epidermal growth factor receptor 2 (HER2) testing for trastuzumab therapy and (2) gene expression profiling (GEP) for adjuvant chemotherapy. HER2 testing for trastuzumab is one of the most successful examples of using a targeted test to determine who should receive a targeted therapy. Women whose tumors over-express HER2 may benefit from trastuzumab, but women whose tumors do not over-express HER2 do not benefit from the medication. HER2 testing is recommended for all patients with invasive breast cancer, 12, 13 and only patients with positive test results are recommended for trastuzumab treatment.
14 Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are 2 tests approved to assess HER2 status. Generally, there are no unique codes to distinguish this medical indication for IHC and FISH testing, thus making the tracking of HER2 tests in claims data challenging. HER2 may also be bundled into one pathology charge and may not appear as a distinct service.
GEP is used to predict the likelihood that a patient will benefit from adjuvant chemotherapy. GEP coverage is generally restricted to patients who may benefit from testing, for example, early-stage, estrogen-receptor-positive breast cancer patients. GEP is expensive at $3650 per test 15 compared with <$100 for IHC and $300 to $400 for FISH 16 to test HER2 status. Since 2006, GEP has had a unique billing code.
The objective of this study was to examine the agreement between administrative claims and medical record data from a large insurer on the utilization of personalized medicine technologies for women with incident breast cancer. We hypothesized that agreement may vary by factors that facilitate tracking of services in administrative claims (eg, coding practices and the cost of the service) and by factors that enhance the completeness of medical record data (eg, obtaining records from multiple vs. single providers of care). Using the examples of HER2 testing for trastuzumab therapy and GEP for adjuvant chemotherapy, we examined both testing and subsequent treatment as they are provided jointly as targeted therapies.
METHODS

Study Population
The study population included 775 women, aged 35 to 65 years, with incident breast cancer diagnosed from July 1, 2006 through June 30, 2007 and 3 years of continuous health insurance coverage from Aetna Inc, a national health benefits company. We identified 2121 women with incident breast cancer, using established algorithms from claims data. 4, 17 The study sample was limited to women with invasive breast cancer (n = 787). We further excluded those with Stage IV cancer (n = 7) and missing stage information (n = 5). All women included in the analysis were confirmed as having incident breast cancer in medical records. Details about sample identification and sample characteristics can be found elsewhere (J. Haas et al, unpublished data, 2010).
All study participants had health insurance coverage for HER2 tests, GEP, trastuzumab, and adjuvant chemotherapy. Aetna's coverage for GEP is limited to the Oncotype Dx Breast Cancer Assay (Redwood City, CA) technology and for individuals whose tumor meets the following clinical criteria: estrogen-receptor-positive; lymph node-negative; and <1 cm in size if HER2-positive or any size if HER2-negative, intermediate, or unknown; these results are used to guide treatment decisions. 18 Women who met these clinical criteria (n = 393) (hereafter referred to as the GEP sample) were examined for GEP and adjuvant chemotherapy analysis.
Data Sources
We obtained data from administrative claims, plan enrollment information, and at least one medical record for all study participants.
Administrative Claims
Administrative claims data are derived from claims submitted by health care providers to obtain payment for services rendered. Three components were included in our study.
Medical claims. We used the medical claims as the primary data component to capture billing codes for HER2, GEP, trastuzumab, and adjuvant chemotherapy. Fully adjudicated medical claims were available from the Aetna central repository. Each claim has up to 4 diagnoses recorded with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes, up to 4 procedures recorded with ICD-9-CM procedure codes, 1 primary procedure recorded with Current Procedural Terminology (CPT) or Healthcare Common Procedure Coding System (HCPCS) code, revenue codes, and other relevant information such as date of service, site of service, and provider specialty codes.
Pharmacy claims. We also reviewed fully adjudicated pharmacy claims. Pharmacy claims data include national drug code, date the prescription was filled, days of supply, and quantity.
Patient enrollment file. We also obtained data from the health plan enrollment file, which provides information on patient age, health plan type, and geographic location.
Medical Record
Requests for medical records were directed to the primary medical oncologist and the primary surgeon identified in claims, defined as the medical oncologist and surgeon, providing the majority of visits to the patient during the 6 months after breast cancer diagnosis. Data were abstracted from available record(s). Among the 775 women with a medical record review, 7.6% had a record from the primary medical oncologist only, 9.7% had a record from the primary surgeon only, and 82.7% had records from both providers. Medical record data were reviewed for the clinical information up to 6 months after the breast cancer diagnosis.
We developed a standard medical record abstraction tool to collect detailed clinical information including record of HER2, GEP test, trastuzumab, or adjuvant chemotherapy. Trained data abstractors reviewed records, and we conducted quality assurance to ensure the accuracy of medical record data. Inter-rater agreement on use of testing-and cancerspecific variables between the abstractor and Ms. Keohane (coauthor, research nurse) was 91% when a sample of 35 medical records was tested over the course of the study.
Variables
We created 2 sets of variables to document the use of HER2 testing, GEP, trastuzumab, and adjuvant chemotherapy according to the evidence of use in each of the data sources.
Evidence of HER2 Testing, GEP, Trastuzumab, and Adjuvant Chemotherapy in Administrative Claims
First, we identified the use of HER2 testing, GEP, trastuzumab, and adjuvant chemotherapy in administrative claims using relevant billing codes (Table 1) . We identified HER2 testing in claims if women with incident breast cancer had a claim with CPT codes for FISH or IHC within 6 months after breast cancer diagnosis. GEP testing was identified using the specific HCPCS code. Trastuzumab therapy was identified using either the HCPCS code in the medical claims or national drug code in the pharmacy claims. Adjuvant chemotherapy administration was identified using ICD-9-CM diagnostic and procedure codes, CPT codes for chemotherapy services and procedures, or HCPCS codes for selected chemotherapy agents. 17 We did not use CPT modifiers and Diagnosis-Related Group codes as they were not available in our database.
Evidence of HER2 Testing, GEP, Trastuzumab, and Adjuvant Chemotherapy in Medical Record
Second, we identified the use of HER2 testing, GEP, trastuzumab, and adjuvant chemotherapy according to the evidence in the medical record. Data abstractors performed a structured medical record review using specific definitions and directions in a coding manual (Table 1) .
Statistical Analysis
We calculated the utilization rate of each test and treatment from administrative claims and medical records, respectively. We tested whether the proportion of women with evidence of use in the medical record equaled the proportion of women with evidence of use in the administrative claims. To determine the agreement between administrative claims and medical records, we compared the evidence of use per woman. We considered 2 scenarios when assessing the agreement between the 2 data sources. First, we assumed that none of the data source was perfect and used the following 3 primary measures to assess the level of agreement: the percent overall agreement (agreement on positives and negatives), percent positive agreement (the ratio of positives identified in both data sources to the average value of positives from either data source), and percent negative agreement (the ratio of negatives identified in both data sources to the average value of negatives from either data source). Second, we treated medical record data as the gold standard and calculated the sensitivity (proportion of true positives), specificity (proportion of true negatives), positive predictive values, and negative predictive values of the administrative claims data in identifying test and treatment utilization.
As a supplementary measure of agreement, we also calculated the kappa statistic. The kappa statistic is known to be sensitive to prevalence and unbalanced margin totals. [19] [20] [21] [22] [23] We used this statistic to categorize the level of agreement based on Landis and Koch's classification 24 : slight agreement (<0.2), fair agreement (0.21 to 0.40), moderate agreement (0.41 to 0.60), substantial agreement (0.61 to 0.80), and almost perfect agreement (0.81 to 1.00).
STATA version 10 was used for all statistical analyses (StataCorp, College Station, TX). The study protocol was reviewed and approved by the Institutional Review Boards of the University of California, San Francisco and Partners HealthCare, Boston.
RESULTS
Utilization Rate of HER2, GEP, Trastuzumab, and Adjuvant Chemotherapy
Utilization of HER2 testing was significantly different between the medical records and claims (Table 2 ). Of total, 97% of women had a documentation of HER2 testing in the medical records, whereas only 76.5% had a HER2 testing in claim (P<0.001). There was a trend that the GEP utilization rate in claims was higher than the rate in the medical records (30.8% vs. 24.9%, P = 0.07). The difference in the utilization of trastuzumab and adjuvant chemotherapy between medical record and claims data was not statistically significant (13.4% vs. 11.9%, P = 0.36 for trastuzumab; 38.9% vs. 43.3%, P = 0.22 for adjuvant chemotherapy).
Patterns of Agreement and Disagreement
We found discrepancies between the medical records and claims for both testing and treatment (Table 3) . HER2 testing and trastuzumab were more often documented in medical records. Approximately 20% of women had no claim consistent with a HER2 test, but had one documented in the medical record. Only 2% had a claim consistent with a HER2 test, but did not have a test documented in the medical record. In contrast, we found that GEP and adjuvant chemotherapy were more often documented in claims. Of all the women eligible for GEP, 7% had a GEP claim without documentation in the medical record; more than 1% had GEP documented in the record but not in claims.
Agreement Between Data Sources: Testing
Agreement between data sources varied by test type ( Table 4 ). The overall agreement was 75.2% for HER2. The kappa statistic was 0.014, categorizing the level of agreement as "slight." When the medical record was treated as the gold standard, sensitivity, the proportion of women with HER2 in claims to all women with HER2 documentation in records, was 76.7%. Specificity, the proportion of women without HER2 in claims to all women without HER2 in records, was 29.2%. GEP had greater agreement than HER2; the overall agreement of claims and records was 91.6%. The kappa statistic was 0.792, categorizing the GEP agreement as "substantial." When the medical record was treated as the gold standard, sensitivity and specificity were 94.9% and 90.1%, respectively.
Agreement Between Data Sources: Treatment
Overall, the agreement for the 2 treatments was high (Table 3) . For trastuzumab, the overall agreement was 95.1%. When the medical record was treated as the gold standard, sensitivity was 76.0% and specificity was 98.1%.
For adjuvant chemotherapy, the overall agreement was 90.0%. When the medical record was treated as the gold standard, sensitivity was 92.1% and specificity was 87.9%. The kappa statistic categorized the agreement for both treatments as "substantial" (k = 0.778 for trastuzumab; k = 0.785 for adjuvant chemotherapy).
Agreement Between Data Sources by the Number of Records Reviewed
There was a trend that women with 2 records reviewed were more likely to have consistent documentation of use in both data sources (medical records and claims) than women with only 1 record reviewed (Table 5 ). Among those with only 1 record reviewed, there was a trend that women with a record from the oncologist were more likely to have consistent documentation of GEP use than women with a record from the surgeon.
DISCUSSION
This study examined the agreement between 2 widely used and important data sources, administrative claims and medical record data, in identifying 2 pairs of targeted tests and treatments (HER2 and trastuzumab; GEP and adjuvant chemotherapy) for breast cancer patients. Our study contributes to the existing literature by examining personalized medicine technologies and by examining whether the agreement varies by the number of records reviewed and provider specialty. Overall, we found good agreement between claims and medical records for GEP, trastuzumab, and chemotherapy, but poor agreement for HER2. A higher level of overall agreement, negative agreement, and specificity was associated with availability of unique billing codes (GEP vs. HER2, trastuzumab vs. chemotherapy) and cost (GEP vs. HER2). There was a trend that greater agreement was associated with multiple records reviewed.
Our study observed 90% to 95% overall agreement for GEP, trastuzumab, and adjuvant chemotherapy. This level of agreement in a commercially insured population is comparable with studies of the Medicare population. These studies found a high agreement between Medicare claims and medical records of hospitals or treating physicians for chemotherapy 1, 7, 25 (94% to 97% overall agreement), for cancer surgery procedures 3, 26 (90% overall agreement, 0.70 GEP indicates gene expression profiling; HER2, human epidermal growth factor receptor 2.
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We observed that the documentation of GEP and adjuvant chemotherapy was higher in claims than in medical records, and that about 7% of the GEP-eligible sample had a claim for GEP or chemotherapy but no documentation in the records. Similar to our observation, Du et al 1 found that many patients had a claim of chemotherapy but no documentation in their medical records and suggested that potential reasons may include erroneous claims or incomplete medical record data. We expected that our study period would capture the majority of testing and treatment, given that GEP tests were typically administered at the time of breast cancer diagnosis or shortly thereafter and that SEERMedicare studies found most patients had a claim of cancer treatment within 2 months. 26 However, our medical record data would have been incomplete if GEP tests were ordered by other providers, if medical records were missing laboratory reports, or if chemotherapy was administered by the medical oncologist but the record was requested from the primary surgeon only.
We found that patterns of agreement (or disagreement) varied by the type and characteristics of services. One interesting observation of the 2 test/treatment pairs was that higher overall agreement, higher negative agreement, and higher specificity were associated with unique billing codes (GEP vs. HER2, trastuzumab vs. chemotherapy) and costs (GEP vs. HER2). Data quality and completeness may have been associated with specific characteristics of services--costs, coverage policy, and coding. We observed lower utilization, lower overall agreement, lower negative agreement, and lower specificity in claims documentation for HER2 than for GEP. A substantial proportion (22.6% of the study sample) had either the IHC or FISH test documented in the record but not in claims. HER2 might have been less identifiable in claims than GEP because it was less expensive, lacked specific codes to distinguish IHC and FISH testing for other purposes, or represented "bundling" of codes under a larger pathology payment category. It was interesting to discover that GEP had a higher rate in claims than in the medical record. For expensive tests and treatment, costs may have created a strong incentive for developing specific codes for billing and reimbursement, thus improving the quality of administrative claims for identifying the use of such services.
Our findings supported the value of reporting overall and individual agreement measures in addition to kappa for a full evaluation of agreement and to avoid potential bias due to prevalence and sampling, as recommended by other studies. [19] [20] [21] [22] [23] We observed an extremely low kappa value (k = 0.014) for HER2, a test for which 96.9% of the study sample had documentation in their medical records. Kappa may not be an appropriate measure for our study, given that HER2 is recommended for all invasive breast cancer patients, and thus we expected a high prevalence rate. This observation is consistent with prior studies that demonstrate a paradoxically low kappa coexistent with high agreement, due to unbalanced margin totals (eg, the "Yes" group in the claims and the "Yes" group in the medical records were substantially greater than 50% of the total sample). 20 Our study had several limitations. The medical record data could have been incomplete because we did not conduct a record review of all providers. We requested data from the primary medical oncologist and the primary surgeon because their records should have captured the majority of tests and treatments for the patients and were the best choices, given limited resources. However, multiple records were not available for all patients. Second, our analysis was based on fully adjudicated claims in only the Aetna system. We would not have captured the claims paid in full by another plan for women with secondary medical coverage. Our claims may have been incomplete due to coordination of benefits and the order of payment, although we expect this was uncommon. Third, we could not have distinguished whether the medical records were electronic or paper-based. Electronic medical records were expected to improve efficiency and reduce transcription errors, thereby improving the accuracy and completeness of medical record data. To compensate, we conducted training for abstractors and provided specific instructions to identify the information for abstraction. Although the time and effort to abstract the medical records may have varied between paper-based and electronic medical records, we expected minimal effect of different medical record systems on data quality and completeness for our study. Finally, perhaps the true gold standard does not exist, given the potential incompleteness of medical records. One possible strategy to counter this potential limitation would have been to implement a standardized prospective data collection method. Such prospective data collection would have given an indication of the accuracy of both medical records and claims data.
Overall, we examined the agreement for 2 pairs of targeted tests and treatments between administrative claims and medical record data. We found good agreement between the 2 data sources for GEP, trastuzumab, and adjuvant chemotherapy, but relatively poor agreement for HER2.
For health services and outcomes research, choosing one source individually versus multiple sources will depend on the study goal, data need and availability, and the characteristics of services under consideration. Our findings demonstrate several implications on the choice of data sources for examining personalized medicine technologies. Administrative claims appear to be sufficient for tracking the use of genomic tests and treatments that have specific billing codes. Medical records are the preferred data source for studies that either require detailed clinical information unavailable in claims or examine the use of genomic tests and treatments without specific billing codes.
Our findings serve as the first step toward evaluating data sources and building an evidence base for examining the utilization of personalized medicine, as well as more general tests and treatments with similar characteristics. Emerging personalized medicine technologies may present new challenges for researchers, compared with traditional treatments and therapies, due to their evolving reimbursement and coverage policies and coding issues. 27 More research is needed to further examine the development of coding for emerging technologies; how such effort can contribute to building an evidence base for clinical practice and policies, and the potential effect of misclassification based on one imperfect data source on utilization and health outcomes.
